Related Experiment Video
Updated: May 4, 2026
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and
Background:
Various microRNAs (miRNAs) are up- or downregulated in tumors. However, the repression of cognate miRNA targets responsible for the phenotypic effects of this dysregulation in patients remains largely unexplored. To define miRNA targets and associated pathways, together with their relationship to outcome in breast cancer, we integrated patient-paired miRNA-mRNA expression data with a set of validated miRNA targets and pathway inference.
Results:
To generate a biochemically-validated set of miRNA-binding sites, we performed argonaute-2 photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (AGO2-PAR-CLIP) in MCF7 cells. We then defined putative miRNA-target interactions using a computational model, which ranked and selected additional TargetScan-predicted interactions based on features of our AGO2-PAR-CLIP binding-site data. We subselected modeled interactions according to the abundance of their constituent miRNA and mRNA transcripts in tumors, and we took advantage of the variability of miRNA expression within molecular subtypes to detect miRNA repression. Interestingly, our data suggest that miRNA families control subtype-specific pathways; for example, miR-17, miR-19a, miR-25, and miR-200b show high miRNA regulatory activity in the triple-negative, basal-like subtype, whereas miR-22 and miR-24 do so in the HER2 subtype. An independent dataset validated our findings for miR-17 and miR-25, and showed a correlation between the expression levels of miR-182 targets and overall patient survival. Pathway analysis associated miR-17, miR-19a, and miR-200b with leukocyte transendothelial migration.
Conclusions:
We combined PAR-CLIP data with patient expression data to predict regulatory miRNAs, revealing potential therapeutic targets and prognostic markers in breast cancer.
Insights
This study identifies specific microRNAs (miRNAs) and their targets in breast cancer subtypes, revealing potential diagnostic markers and therapeutic strategies for improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- MicroRNAs (miRNAs) are frequently dysregulated in tumors, but their target repression's phenotypic impact in patients is understudied.
- Understanding miRNA target repression is crucial for elucidating breast cancer pathogenesis and identifying therapeutic targets.
Purpose of the Study:
- To define miRNA targets and associated pathways in breast cancer.
- To investigate the relationship between miRNA dysregulation and patient outcomes.
- To integrate patient data with validated miRNA targets and pathway inference.
Main Methods:
- Generated biochemically-validated miRNA-binding sites using argonaute-2 photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (AGO2-PAR-CLIP) in MCF7 cells.
- Defined putative miRNA-target interactions using a computational model integrated with AGO2-PAR-CLIP data.
- Subselected interactions based on miRNA/mRNA transcript abundance and tumor expression variability to detect miRNA repression.
Main Results:
- Identified subtype-specific miRNA regulatory activity, with miR-17, miR-19a, miR-25, and miR-200b prominent in triple-negative breast cancer, and miR-22/miR-24 in HER2-subtype.
- Validated findings for miR-17 and miR-25 in an independent dataset.
- Correlated miR-182 target expression with overall patient survival and linked miR-17, miR-19a, miR-200b to leukocyte transendothelial migration.
Conclusions:
- Combined PAR-CLIP and patient expression data to predict regulatory miRNAs in breast cancer.
- Revealed potential therapeutic targets and prognostic markers through integrated analysis.
- Highlighted subtype-specific miRNA roles in breast cancer progression and patient outcomes.
